Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2026 Earnings Presentation
17 slides from Bactiguard Holding Ab's earnings presentation, Apr 23, 2026
Slide 1: Building momentum through partnerships, regulatory progress and organizational strength
Building momentum through partnerships, regulatory progress and organizational strength Q1 presentation Thursday 23 April 2026 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Continued progress in executing Bactiguard’s strategy
Continued progress in executing Bactiguard’s strategy Key figures for Q1 2026 (Q1 2025) Highlights Q1 • BD has now begun sales of Bactiguard- Total revenue 46.9 (62.7) MSEK coated products in parts of Europe • First quarter under the updated business Adj. EBITDA 4.9 (9.4) MSEK setup with Zimmer Biom
Slide 3: High level of business development activity across our strategic therapeutic areas
High level of business development activity across our strategic therapeutic areas Partnership snapshot Q1 2026 Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Other 3 Average 5-7 yea
Slide 4: BD Partnership – Increasing market presence
BD Partnership – Increasing market presence • Collaboration spanning entire value chain – from technology licensing to go-to-market strategies • Continue to support market penetration in India after launch of Bactiguard-coated Foley catheters in 2025 • BD initiated commercial sales of Bactiguard-coa
Slide 5: Zimmer Biomet partnership – First quarter under the updated business setup
Zimmer Biomet partnership – First quarter under the updated business setup • Partnership focused on commercialization of the ZNN Bactiguard trauma nail system • ZNN Bactiguard continues to expand across Europe and key Middle East markets • Collaboration on MDR submission activities is ongoing • Clin
Slide 6: Wound Management – Solid performance driven by Hydrocyn aqua
Wound Management – Solid performance driven by Hydrocyn aqua • Hydrocyn continues to deliver strong growth, supported by continued market expansion • Stabilization of sutures sales • MDR-related activities well underway across both business areas • High comparison quarter vs. Q1 2025 due to periodiz
Slide 7: Total revenues decreased 16% excl. negative currency effects
Total revenues decreased 16% excl. negative currency effects mainly driven by high comparisons for BD and WM Revenue development First quarter (Jan-Mar) Full year RTM MSEK reported (excl. FX) 237.7 228.6 0.9 9.6 0.3 9.6 63.8 62.7 Other revenues BIP portfolio Wound Management portfolio Total license
Slide 8: License revenue declined 20% driven by BD
License revenue declined 20% driven by BD, despite increases from ZB and Application Development License revenue development First quarter (Jan-Mar) Full year RTM MSEK reported (excl. FX) 163.3 156.0 0.0 0.3 0.0 1.3 Application development partners Exclusivity partners License partners 163.0 154.7 -
Slide 9: Costs decreased 8% in the quarter while we continue to invest
Costs decreased 8% in the quarter while we have strengthened the organization and will continue to invest Total operating costs (OPEX) development First quarter (Jan-Mar) Full year RTM MSEK 153.7 150.4 Personnel costs 95.4 93.7 Other external expenses Other operating expenses -7.9% 42.4 39.0 23.1 21
Slide 10: 4.9 MSEK in Adjusted EBITDA with RTM still close to 40 MSEK
For the first quarter, we deliver 4.9 MSEK in Adjusted EBITDA with RTM still close to 40 MSEK Adjusted EBITDA development First quarter (Jan-Mar) Full year RTM MSEK 43.8 39.3 Adjusted EBITDA -4.5 9.4 4.9 2025 2026 2025 2025/26 10 Source: Bactiguard Holding AB, Interim report Q1 2026, p. 16
Slide 11: Cash flow negative mainly driven by changes in working capital
In Q1, cash flow for the period was negative SEK 10.1 mainly driven by changes in working capital Cash flow for the period and total cash development MSEK 44.3 -7.4 -0.9 -1.8 1.2 35.3 Cash end Cash flow Cash flow Cash flow Exchange Cash end of Q4 2025 from operating from investing from financing dif
Slide 12: Continue to build on strategy towards targets 2030
Continue to build on strategy towards targets 2030 Strategic focus Targets by year-end 2030 application areas License partnerships Advance current and develop new partnerships >10 in either exclusivity or license partnership R&D Medical Continue to invest in key >200 MSEK EBITDA knowledge areas Regu
Slide 13: Questions & Answers
Questions & Answers Q1 presentation Christine Lind Patrick Bach CEO CFO
Slide 14: Additional financial information
Additional financial information
Slide 15: Appendix – Revenue incl. fx
Appendix – Revenue incl. fx Revenue development First quarter (Jan-Mar) Full year RTM MSEK reported (incl. FX) 228.7 212.9 0.9 12.8 0.3 13.6 62.7 Other revenues 60.8 BIP portfolio Wound Management portfolio Total license revenue -25.2% 62.7 152.3 46.9 138.2 0.5 3.7 19.2 0.0 4.5 17.3 39.3 25.1 2025 2
Slide 16: Appendix – License revenue incl. fx
Appendix – License revenue incl. fx License revenue development First quarter (Jan-Mar) Full year RTM MSEK reported (Incl. FX) 152.3 0.0 0.3 138.2 0.0 1.1 Application development partners Exclusivity partners License partners 152.0 -36.1% 137.1 39.3 0.0 0.0 25.1 39.3 0.0 0.9 24.2 2025 2026 2025 2025
Slide 17: Appendix - EBITDA
Appendix - EBITDA EBITDA development First quarter (Jan-Mar) Full year RTM MSEK 43.8 38.5 EBITDA -5.3 9.4 4.1 2025 2026 2025 2025/26 17 Source: Bactiguard Holding AB, Interim report Q1 2026, p. 16